NYSE · Healthcare · Financials
Thermo Fisher Scientific Inc (TMO) financial statements and cash flow.
Revenue, profitability, balance-sheet strength, and cash generation for TMO. Market data source · as of 2026-06-27.
Section freshness
Price Aug 3, 10:33 AM EDT · Statements Jun 26, 8:00 PM EDT
Financial read
TMO latest financial snapshot.
Start with the latest reported values below. Deeper quarterly and annual statement tables follow when supplied.
Revenue
$11.99B
+10.5% YoY
Net income
$1.74B
+5.1% QoQ
Free cash flow
$1.68B
+105.3% QoQ
Net margin
14.47%
Operating margin 17.40%
Balance sheet coverage
TMO balance sheet summary
Assets, liabilities, liquidity, debt, and equity sit beside income and cash-flow tables so the statement history reads as one model-ready dataset.
20 quarterly · 4 annual rows · Market data source · as of 2026-06-27
Latest period
Q2 FY2026
20 quarterly · 4 annual rows
Assets / liabilities
$113.17B
Liabilities —
Cash / debt
$4.06B
Net cash $696.00M
Equity / working capital
$52.68B
Working capital $8.30B
Financial statements
TMO statement coverage.
Income statement, balance sheet, and cash-flow figures for TMO, with quarterly and annual history in the tables below.
Data last updated
Jun 26, 2026
Income periods
24
Balance-sheet periods
24
Cash-flow periods
23
Quarterly and annual TMO statements, sourced from Market data source · as of 2026-06-27.
Financial statement period
TMO statement history
Market data source · as of 2026-06-27 · Data last updated: Jun 26, 2026
Income statement
Quarterly and annual rows for revenue, operating leverage, earnings quality, and margin direction.
| Period | Revenue | Gross profit | Operating income | Interest income | Continuing ops | Net income | Comprehensive income | Net margin | Revenue QoQ | Net income QoQ |
|---|---|---|---|---|---|---|---|---|---|---|
| Q2 FY2026 | $11.99B | $2.09B | $1.74B | 14.47% | +9.0% | +5.1% | ||||
| Q1 FY2026 | $11.01B | $1.86B | $1.65B | 15.00% | -9.9% | -15.9% | ||||
| Q4 FY2025 | $12.21B | $2.25B | $1.96B | 16.08% | +9.8% | +21.5% | ||||
| Q3 FY2025 | $11.12B | $1.94B | $1.62B | 14.53% | +2.5% | -0.1% | ||||
| Q2 FY2025 | $10.86B | $1.83B | $1.62B | 14.90% | +4.7% | +7.3% | ||||
| Q1 FY2025 | $10.36B | $1.72B | $1.51B | 14.54% | -9.0% | |||||
| Q4 FY2024 | $11.39B | $2.02B | +7.5% | |||||||
| Q3 FY2024 | $10.60B | $1.84B | $1.63B | 15.38% | +0.5% | +5.3% |
Balance sheet
Balance-sheet history for assets, liabilities, liquidity, debt, equity, and shares outstanding.
| Period | Cash | Current assets | Current liabilities | Total assets | Total liabilities | Total debt | Capital leases | Total equity | Shares | Debt QoQ |
|---|---|---|---|---|---|---|---|---|---|---|
| Q2 FY2026 | $4.06B | $23.36B | $15.07B | $113.17B | $3.37B | $52.68B | +9.0% | |||
| Q1 FY2026 | $3.25B | $22.32B | $14.62B | $113.28B | $3.09B | $51.93B | -12.5% | |||
| Q4 FY2025 | $9.85B | $28.71B | $15.19B | $110.34B | $3.53B | $53.41B | -7.6% | |||
| Q3 FY2025 | $1.98B | $22.30B | $14.89B | $103.02B | $3.82B | $51.02B | +72.7% | |||
| Q2 FY2025 | $4.58B | $24.58B | $12.72B | $101.23B | $2.21B | $50.51B | -21.5% | |||
| Q1 FY2025 | $4.13B | $23.38B | $13.17B | $99.04B | $2.82B | $49.39B | +27.3% | |||
| Q4 FY2024 | $4.01B | $22.14B | $13.33B | $97.32B | $2.21B | $49.58B | -46.2% | |||
| Q3 FY2024 | $4.64B | $23.78B | $14.60B | $100.36B | $4.12B | $48.99B | -19.6% |
Cash flow
Operating cash generation, capital expenditure, free cash flow, buybacks, dividends, and cash movement.
| Period | Operating cash flow | CapEx | Free cash flow | Net income | Stock comp | Debt issuance | Dividends paid | Buybacks | Change in cash | FCF QoQ |
|---|---|---|---|---|---|---|---|---|---|---|
| Q2 FY2026 | $2.13B | $450.00M | $1.68B | $1.74B | $175.00M | $1.00B | +105.3% | |||
| Q1 FY2026 | $1.19B | $376.00M | $816.00M | $1.65B | $162.00M | $3.00B | -72.7% | |||
| Q4 FY2025 | $3.46B | $465.00M | $2.99B | $1.96B | $162.00M | $37.00M | +63.1% | |||
| Q3 FY2025 | $2.24B | $404.00M | $1.83B | $1.62B | $163.00M | $963.00M | +66.1% | |||
| Q2 FY2025 | $1.40B | $294.00M | $1.10B | $1.62B | $162.00M | — | +206.1% | |||
| Q1 FY2025 | $723.00M | $362.00M | $361.00M | $1.51B | $149.00M | $2.00B | -87.2% | |||
| Q4 FY2024 | $3.29B | $480.00M | $2.81B | $149.00M | $1.00B | +48.4% | ||||
| Q3 FY2024 | $2.17B | $272.00M | $1.89B | $1.63B | $150.00M | — | +14.2% |
Valuation and returns
- Enterprise value
- $212.73B
- TECHi computed
- Return on equity
- 13.23%
- Market data source
- Return on assets
- 6.16%
- Market data source
- Debt / equity
- 0.06
- Current ratio 1.55
Ratio values use provider-attributed fields when available and otherwise fall back to TECHi statement math from the visible rows on this page.
Annual revenue and income multiples
Annual sales and income multiple reads use the latest annual statement when available, then fall back to trailing-twelve-month statement math from the visible quarterly rows.
- Annual revenue base
- $44.56B
- Annual statement 2025-12-31
- Annual income base
- $6.70B
- Annual statement 2025-12-31
- Market cap / annual revenue
- 4.79
- Live market value divided by annual revenue
- Market cap / annual income
- 31.84
- Live market value divided by annual net income
Annual sales and income multiple
Market capitalization bridge
TTM valuation multiples
- TTM revenue
- $46.34B
- Trailing twelve months
- TTM EBIT
- $8.15B
- TTM operating income
- Market cap / TTM revenue
- 4.61
- Live market value divided by trailing twelve months revenue
- EV / TTM revenue
- 4.59
- Enterprise value divided by trailing twelve months revenue
Live market value is matched against trailing-twelve-month statement bases first so the multiple moves with the tape instead of anchoring to stale fiscal-year rows.
Profit multiples
Revenue, net income, and free cash flow
Quarterly statement rows, shown on one common dollar scale so margin compression and cash conversion stand out quickly.
Efficiency
Growth vs cost pressure
Cash conversion
TTM free cash flow / TTM operating income
Quarterly margin heatmap
Latest quarter expense mix
Profit bridge
Other income statement lines
Balance sheet · Q2 FY2026
- Cash & equivalents
- $4.06B
- Total debt
- $3.37B
- Net cash
- $696.00M
- Net cash position
- Total equity
- $52.68B
Balance sheet detail
- Current assets
- $23.36B
- Current liabilities
- $15.07B
- Inventory
- $5.63B
- Receivables
- $9.45B
- Property, plant & equipment
- $10.76B
- Current debt
- $3.37B
Debt and liquidity
Cash + short-term investments + receivables / current liabilities
Cash generation
- Operating cash flow
- $2.13B
- Capital expenditure
- $450.00M
- Free cash flow
- $1.68B
- Capital returned
- $1.18B
- Buybacks + dividends paid
Cash-flow detail
- Investing cash flow
- $164.00M
- Financing cash flow
- -$1.57B
- Buybacks
- $1.00B
- Net buybacks
- $1.00B
- Repurchases less stock issuance
- Dividends paid
- $175.00M
Cash flow read
TMO converts most of its earnings into cash.
Free cash flow of $1.68B versus $1.74B of reported net income means accruals aren't doing much heavy lifting — the cash is showing up alongside the earnings. That's the cleanest profile a fundamentals desk wants to see.
Frequently asked
Common questions.
What financial data is available for TMO?
The TMO Financials page renders only the current income-statement, balance-sheet, cash-flow, or fund rows supplied for Thermo Fisher Scientific Inc. Missing modules and empty line items are omitted.
How current are TMO's financial statements?
Each visible statement row keeps its reported period and provider attribution. The route redirects to the main quote when no usable financial or fund data remains.
What is Thermo Fisher Scientific Inc's reported net margin?
Thermo Fisher Scientific Inc's fresh reported margin field is 15.04%. The Financials page shows the supporting period data currently available for TMO.